Synbio Tech Inc. (TPEX:1295)

Taiwan · Delayed Price · Currency is TWD

50.10

-0.40 (-0.79%)

Jun 18, 2026, 1:30 PM CST

-48.88% (1Y)

Market Cap	1.73B -17.2%
Revenue (ttm)	1.02B +2.5%
Net Income	149.95M -13.1%
EPS	4.40 -19.5%
Shares Out	34.48M
PE Ratio	11.38
Forward PE	n/a
Dividend	3.00 (5.99%)
Ex-Dividend Date	Mar 27, 2026

Volume	87,720
Open	49.65
Previous Close	50.50
Day's Range	48.80 - 50.60
52-Week Range	47.30 - 157.50
Beta	0.51
Analysts	Buy
Price Target	149.00 (+197.41%)
Earnings Date	Aug 10, 2026

About Synbio Tech

Synbio Tech Inc. manufactures and sells human healthcare products and probiotics for animals. It offers lactobacillus plantarum powder and derivatives of fermented lactic acid bacteria, as well as probiotics for dietary supplements, pets, economic animals, and plant preservation. The company also provides single probiotic strain and multi strain probiotics, and functional strain. Its functional strain includes SynForU-MemoryUp, a solution for brain health; Lactobacillus plantarum TWK10 for exercise performance; ABKEFIR to improve digestive and ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 92

Stock Exchange Taipei Exchange

Ticker Symbol 1295

Full Company Profile

Financial Performance

In 2025, Synbio Tech's revenue was 1.04 billion, an increase of 4.97% compared to the previous year's 989.48 million. Earnings were 175.97 million, an increase of 3.43%.

Financial Statements